Fundraising FoxUrigen Pharmaceuticals
North Brunswick, US · Delaware corporation
Find your way into Urigen Pharmaceuticals
Sign up to see every warm intro you have to Urigen Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Urigen Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Urigen Pharmaceuticals develops treatments for interstitial cystitis and related bladder conditions. The company is led by researchers and executives with extensive experience in pharmaceutical development and commercialization.
Founders & leadership
LP
Lowell ParsonsChairman and Scientific Founder
MJ
Mark J. RosenblumExecutiveMark J. Rosenblum is an executive with a background in accounting and financial management across chemical and life sciences companies, including C-level roles at public organizations ranging from $5 million to $1 billion in size. He holds a master's and bachelor's degree in accounting and has been a Certified Public Accountant for over 30 years.
DV
Dan VickeryDirector, COO and President
CL
C. Lowell ParsonsNamed on SEC filing
Board
MG
Michael GoldbergBoard director
MN
Michael NordlichtBoard director
AL
A. Luc MaasdorpBoard director
Reported raises · per SEC filings
Form D private placements$6.2M disclosed across 5 rounds · 2015–2023
▶$1MraisedJan 2024 · 6 investors · PharmaceuticalsRule 506(b)
▶$1MraisedJan 2024 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Daniel VickeryExecutive Officer, Director
- Carlo Di FonzoDirector
- C. Lowell ParsonsDirector
- Robert EvansDirector
- Offering amount
- $5M
- Amount sold
- $1M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedNov 2020 · 32 investors · PharmaceuticalsRule 506(b)
▶$3MraisedNov 2020 · 32 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dan VickeryExecutive Officer, Director
- C. Lowell ParsonsDirector
- Carlo Di FonzoDirector
- Robert EvansDirector
- Offering amount
- $3M
- Amount sold
- $3M
- Minimum investment
- $2.6K
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedFeb 2018 · 22 investors · PharmaceuticalsRule 506(b)
▶$1.4MraisedFeb 2018 · 22 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carlo Di FonzoDirector
- Dan VickeryExecutive Officer, Director
- C. Lowell ParsonsDirector
- Abe HahnDirector
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- Minimum investment
- $13.5K
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedApr 2017 · 5 investors · PharmaceuticalsRule 506(b)
▶$500KraisedApr 2017 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carlo Di FonzoDirector
- C. Lowell ParsonsDirector
- Abe HahnDirector
- Dan VickeryExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $500K
- Minimum investment
- $50K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$300KraisedJul 2015 · 1 investors · PharmaceuticalsRule 506(b)
▶$300KraisedJul 2015 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael GoldbergDirector
- C. Lowell ParsonsDirector
- Michael NordlichtDirector
- Mark J. RosenblumExecutive Officer
- A. Luc MaasdorpDirector
- Offering amount
- $12.4M
- Amount sold
- $300K
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
UrogenUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
1MgThis is a product listing page on an online pharmacy for Tugain Twins 5 Solution, a topical minoxidil-based medicine sold to treat hair loss and promote hair regrowth. The page provides usage instructions, benefits, side effects, and purchase/return details rather than describing a company.
GlobaldataGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
Companies working in the same space as Urigen Pharmaceuticals.
In the news
Frequently asked questions
- What does Urigen Pharmaceuticals do?
- Urigen Pharmaceuticals develops treatments for interstitial cystitis and related bladder conditions. The company is led by researchers and executives with extensive experience in pharmaceutical development and commercialization.
- Who founded Urigen Pharmaceuticals?
- Urigen Pharmaceuticals was founded by Lowell Parsons.
- How much funding has Urigen Pharmaceuticals raised?
- Urigen Pharmaceuticals has disclosed $6.2M raised across 5 rounds.
- Where is Urigen Pharmaceuticals headquartered?
- Urigen Pharmaceuticals is headquartered in North Brunswick, US.